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Abstract 
Background: Breast cancer has the highest cancer incidence in women and is one 
of the leading causes of mortality globally. Lactate dehydrogenase (LDH) and 
other enzymes are vital metabolic enzymes that are associated with cancer 
development, invasion, and metastasis.  
Aim: The present study aimed to evaluate the LDH, Gamma-glutamyl 
transpeptidase (GGT) and Alkaline phosphatase (ALP) levels in the circulation of 
patients of breast cancer in different stages and tried to correlate levels with the 
disease stage and duration of breast cancer with and without lymph node 
involvement.  
Methods: LDH, GGT, and ALP were analyzed by means of the 
spectrophotometer, Biosystem device and reagents, serum samples were used for 
measurement.  
Results: GGT and LDH had a significant difference with P.value 0.022 and 0.001 
respectively between stages II and III, while ALP didn't show a significant 
difference.  
Conclusion: This data concluded that enzyme markers like serum LDH and GGT 
could be sensitive, specific and cost effective biomarkers for diagnosing 
carcinoma of the breast and for monitoring its progression. 
 
Keyword: LDH, GGT, ALP, Breast cancer. 





Breast cancer continues to be a disease with tremendous public health significance 
(1)
. It remains the leading cause of cancer mortality for women in both developed 
countries (30%) and developing countries (14%) 
(2)
 where its incidence rates have 
been continuously rising
3
. It is a disease characterized by prevalence, 
aggressiveness, unequal geographic distribution, and an increasing incidence 
throughout the world 
(4,5)
. Environmental factors, including a nutritious diet, either 
alone or in combination, have been incriminated in the increase in cancer 
incidence rates and in its progressive spread into all regions of the world. Many 
experimental, clinical and epidemiological studies have revealed that a number of 
factors influence breast cancer etiology. Hormonal factors
(6,7)
, reproductive 
factors, genetic factors, lifestyle, and dietary factors
(8)
.  Primary prevention of 
breast cancer is still not available except by extreme measures such as a 
prophylactic mastectomy for women who are genetically at high risk, so efforts to 
promote early detection continue to be the major focus in fighting breast cancer. 
The goal of early detection is to diagnose and treat breast cancer patients at an 
early stage when the prognosis for long-term survival is best. Prognosis is 
generally more favorable for women with an early-stage disease than for those 




Aberrant energy metabolism is a common feature of cancer 
(10)
. In normal cells, 
when oxygen is available, pyruvate generated during the breakdown of glucose is 
utilized to produce energy through oxidative phosphorylation. In contrast, tumor 
cells prefer pyruvate metabolism via the anaerobic pathway regardless of oxygen 
availability, leading to inefficient fuel production and formation of lactate. This 
anomalous metabolic preference is known as the Warburg effect or ‘aerobic 
glycolysis 
(11,12)
. Lactate dehydrogenase (LDH) is the enzyme responsible for the 
conversion of pyruvate to lactate during glycolysis 
(13)
. It is expressed in all tissues 
and its A and B subunits, coded by two different genes LDH-A and LDH-B, 
combine to construct five iso-enzymes (LDH1 to LDH5) with selective 
distribution among tissues and in serum 
(14)
. In addition, LDH is known as a 




marker for tissue injury, inflammation, hemolysis, and myocardial 
infarction
(15,16,17)
. Elevated LDH levels are seen in cancer patients, and its 
prognostic value has been shown in several malignancies such as germ cell 
tumors, lymphoma, melanoma, and renal cell carcinoma
(18,19,20,21)
. Recent 
evidence linking LDH-A and the oncogene c-MYC suggests that metabolic 
derangements may occur before the tumor becomes macroscopic, that is before it 
is clinically detectable
(22)
. The role of these early metabolic disturbances in the 
context of cancer survival remains poorly understood. Currently, there is also a 




Gamma-glutamyltransferase (GGT) is a cell-membrane bound enzyme 
(24)
, widely 
present on the external surface of most cells
(25)
, with high secretory activity like 
liver, kidneys and pancreas 
(24)
. GGT is responsible for the glutathione (GSH) 
metabolism, catalyzing the degradation of extracellular GSH and further 
promoting amino-acid recovery for subsequent intracellular GSH synthesis
(26)
. 
Intracellular GSH acts as an antioxidant, neutralizing free radicals and so plays a 
decisive role in protection against oxidative stress during cell metabolism 
(25)
. 
Therefore, GGT and GSH are increasing in circumstances of oxidative stress like 
carcinogenesis 
(26)
 and have been implicated in numerous other diseases like 
cardiovascular disease, diabetes, metabolic syndrome, malignancies and is 
associated with an increase in all-cause mortality
(27,28)
. 
Alkaline phosphatases are a group of phosphatidylinositol-anchored membrane 
proteins with wide substrate specificity 
(29,30)
. It comprises a group of enzymes 
that catalyze the hydrolysis of phosphate esters in an alkaline environment, 
generating an organic radical and inorganic phosphate 
(31)
. Like other enzymes, 
ALP has many iso-enzymes. In healthy adults, this enzyme is mainly derived from 
the liver, bones and in lesser amounts from intestines, placenta, kidneys and 
leukocytes 
(32)
. An increase in serum ALP levels is frequently associated with a 
variety of diseases such as extrahepatic bile obstruction, intrahepatic cholestasis, 
infiltrative liver disease, hepatitis and cancer,  However, the elevation of ALP less 
than three times the normal level is generally considered to be non-specific and 
insufficient to provide a definite diagnosis 
(33)
. 




Materials and methods 
Fifty women diagnosed with breast cancer were involved in this cross-sectional 
study, they attended Khartoum Oncology Hospital for diagnosis, treatment and 
follow up. They were diagnosed and classified in groups according to the grade, 
grade I, II and III. Approval of the study to be performed was obtained from each 
patient and hospital administration as well. Under hygienic condition blood was 
withdrawn in plane containers from each subject considering labeling and data 
obtained from each one, blood allowed for clot formation and subsequent serum 
separation which was preserved at -20 for later chemical analysis. Chemical 
analysis targeted enzymes, GGT, LDH, and ALP, they were measured by means 
of spectrophotometer method, using Biosystem device, reagents were Biosystem 
trademark, they were ready to use. 
 
Results 
A total of 50 women with an established diagnosis of breast cancer were involved 
in this study, the mean+SD of the duration of the disease was (3.52+1.89) years 
and their age mean+SD was (38.1+6.31) years as in table 1. 
  
Table (1): Age and duration of breast cancer  
Parameters Minimum Maximum Mean±SD 
Age (Years) 26.00 49.00 38.10±6.31 
Duration (Years) 1.00 8.00 3.52±1.89 
 
Blood samples were sent for measurement of GGT, LDH, and ALP. The results 
obtained were analyzed statistically and the p value of 0.05 consider significant. 
Data gave significant difference for both ALP and LDH with P-value 0.000 and 
0.036 respectively and no significant difference with GGT with p-value 0.298 as 
in table 2.  
 




Table (2): Mean+SD of ALP, GGT and LDH among breast cancer women 
and control 





LDH (U/L) 455.50±54.54 337±95 0.000 
ALP (U/L) 88.52±20.88 70±25  0.036 
GGT (U/L) 38.56±16.39 41±7 0.298 
 
In this study a highly significant increase in mean serum of ALP and GGT was 
observed in carcinoma breast patients when compared to controls (P < 0.000). 
Enzymes levels among the three grades of breast cancer brought significant 
difference for LDH at grade II and III as p.values 0.022 and 0.001 respectively, 
but ALP didn't show any difference among the three grades while GGT has an 
only significant difference at grade III as p.value 0.022 as in table 3. 
 
Table (3): LDH, ALP, and GGT among the three grades of breast cancer 






LDH (U/L) 128.66±14.04 186.00±42.28 204.86±59.14 
P-value   0.022 0.001 
ALP (U/L) 65.33±5.50 62.44±23.57 67.44±20.33 
P-value  0.234 0.112 
GGT (U/L) 28.66±13.31 34.27±12.06 42.24±18.24 
P-value  0.324 0.022 
Significant difference as p.value <0.05 
Correlation of enzymes level and duration of breast cancer show no significant 
correlation, but only GGT has a significant negative correlation as in figure 1, 2 
and 3. 
 




Figures (1) and (2): Show correlation analysis between duration and LDH      




Figure (3): Shows the correlation between duration and GGT 
 
Discussion 
Breast cancer is the second most common cancer worldwide after lung cancer, the 
fifth most common cause of cancer death, and the leading cause of cancer death in 
women. The global burden of breast cancer exceeds all other cancers and the 
incidence rates of breast cancer are increasing 
(34)
. In this study measured 
parameters (LDH, GGT, and ALP) were conducted among breast cancer women 
in Khartoum oncology hospitals, they were sorted to 3 stages I, II and III, data 
obtained compared with normal range gave significant difference LDH for grade 
II and III. 
For enzymes levels among the 3 grades of breast cancer, grade I showed no 
change or no difference as the other grades have, a significant difference for LDH 
for both grades II and III as p values 0.022 and 0.001 respectively, GGT brought 




significant difference with grade III with p. value 0.022 and ALP did not bring 
any difference among the three grades while GGT has only significant difference 
at grade III as p.value 0.022, this in agreement with a study concerned about the 
same manner and enzymes, referring that these enzymes  play potential roles in 
tumor growth and have prognostic relevance in a diverse array of tumors, it found 
increased level of the 3 enzymes ALP, LDH and GGT than normal limits and 
mentioned that LDH increased had poor effects on both overall survival and 
distant metastasis-free survival with P 0.009 and 0.035 respectively and ALP had 
poor effects on both overall survival and local recurrence-free survival (P = 0.037 
and 0.039, respectively
(35)
.  Considering finding of ALP in this study ( p-value 
0.23 and 0.11 for both grades II and III), it disagrees with other Indian study 
measured ALP only among breast cancer patients  and observed ALP has increase 
level found among women with grade IV with P value <0.001, revealing  that 
ALP can be used for differentiation of stages of breast cancer 
(36)
.  Somehow our 
study agrees with other study included 102 confirmed cases of carcinoma breast 
with and without metastasis and 25healthy non-pregnant females. They were 
evaluated for blood levels of LDH, ALP, and GGTand other parameters before 
and 21 days after mastectomy. A significant increase (p<0.001) was observed in 
LDH level in cancer patients without metastasis in comparison to normal control 
subjects. Patients with metastasis had further elevated (P)<0.001) levels of ALP 
and GGT as compared to non-metastatic patients. Mastectomy in both the cases 
i.e. with and without metastasis resulted in a non-significant decrease in all the 
biochemical parameters suggesting that longer follow up could confirm post 




Enzymes measured in this study (LDH, ALP, and GGT) were found elevated and 
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